Skip to main content
OTCMKTS:CDSG

China Dongsheng International Competitors

$0.06
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
$0.06
50-Day Range
$0.01
$0.14
52-Week Range
$0.00
$0.25
VolumeN/A
Average Volume17,567 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta13.38

Competitors

China Dongsheng International (OTCMKTS:CDSG) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CHHE

Should you be buying CDSG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to China Dongsheng International, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Health Industries (CHHE).

Acusphere (OTCMKTS:ACUS) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Profitability

This table compares Acusphere and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Acusphere and China Dongsheng International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
China Dongsheng International0000N/A

Risk and Volatility

Acusphere has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its share price is 1,238% more volatile than the S&P 500.

Earnings and Valuation

This table compares Acusphere and China Dongsheng International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Summary

China Dongsheng International beats Acusphere on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Affymax (OTCMKTS:AFFY) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares China Dongsheng International and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
AffymaxN/AN/AN/A

Valuation and Earnings

This table compares China Dongsheng International and Affymax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for China Dongsheng International and Affymax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
Affymax0000N/A

Volatility and Risk

China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

China Dongsheng International beats Affymax on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for ARYx Therapeutics and China Dongsheng International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
China Dongsheng International0000N/A

Risk and Volatility

ARYx Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, suggesting that its stock price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares ARYx Therapeutics and China Dongsheng International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Summary

China Dongsheng International beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and AtheroNova (OTCMKTS:AHROQ) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for China Dongsheng International and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
AtheroNova0000N/A

Profitability

This table compares China Dongsheng International and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
AtheroNovaN/AN/AN/A

Volatility and Risk

China Dongsheng International has a beta of 13.38, suggesting that its share price is 1,238% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, suggesting that its share price is 971% less volatile than the S&P 500.

Earnings and Valuation

This table compares China Dongsheng International and AtheroNova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Summary

China Dongsheng International beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Risk and Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for China Botanic Pharmaceutical and China Dongsheng International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
China Dongsheng International0000N/A

Profitability

This table compares China Botanic Pharmaceutical and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Valuation & Earnings

This table compares China Botanic Pharmaceutical and China Dongsheng International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Summary

China Botanic Pharmaceutical beats China Dongsheng International on 1 of the 1 factors compared between the two stocks.

China Health Industries (OTCMKTS:CHHE) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Volatility & Risk

China Health Industries has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its share price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares China Health Industries and China Dongsheng International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

China Health Industries has higher revenue and earnings than China Dongsheng International.

Profitability

This table compares China Health Industries and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Health Industries34.11%8.60%7.05%
China Dongsheng InternationalN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for China Health Industries and China Dongsheng International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Health Industries0000N/A
China Dongsheng International0000N/A

Summary

China Health Industries beats China Dongsheng International on 4 of the 5 factors compared between the two stocks.


China Dongsheng International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00High Trading Volume
Gap Down
ARYX
ARYx Therapeutics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Up
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.95flat$0.00N/A0.00Gap Down
HRBR
Harbor Diversified
0.0$1.70flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.